Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Non Operating Income (2020 - 2023)

Candel Therapeutics' Non Operating Income history spans 4 years, with the latest figure at -$777000.0 for Q4 2023.

  • For Q4 2023, Non Operating Income fell 125.74% year-over-year to -$777000.0; the TTM value through Dec 2023 reached $452000.0, down 97.16%, while the annual FY2024 figure was -$21.8 million, 4924.34% down from the prior year.
  • Non Operating Income for Q4 2023 was -$777000.0 at Candel Therapeutics, down from $426000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $9.3 million in Q4 2021 and bottomed at -$8.1 million in Q3 2021.
  • The 4-year median for Non Operating Income is $310500.0 (2020), against an average of $1.0 million.
  • The largest annual shift saw Non Operating Income plummeted 4270.77% in 2021 before it soared 4431.84% in 2022.
  • A 4-year view of Non Operating Income shows it stood at -$4.4 million in 2020, then skyrocketed by 312.96% to $9.3 million in 2021, then plummeted by 67.66% to $3.0 million in 2022, then plummeted by 125.74% to -$777000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Non Operating Income are -$777000.0 (Q4 2023), $426000.0 (Q3 2023), and -$35000.0 (Q2 2023).